TICKERNERD
Menu
MEDMEDConsumer Cyclical · Personal Services

MED Stock Forecast: Medifast, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$12
−1.59% on the day

The 1 Wall Street analysts covering Medifast, Inc. hold a median 12-month price target of $12 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 17 Sept 2026 — in the lower half.

Market cap
$133.7M
Ticker Nerd rank
48 / 100
Median analyst target
$12
Analysts covering
1
Revenue$76.4M−27.6% y/y
Operating income−$4.3M
Net income−$3.1M
Free cash flow$728K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.2%
1M
+4.3%
YTD
+10.2%
1Y
−19.2%
From 52W high
−19.2%
From 52W low
+24.6%
$9
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MED stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medifast, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Revisions
86
Size
72
Quality
45
Momentum
40
Volatility
32
Growth
30
Issuance
28
Value
7

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$9$10$11$12$13$14$15Oct 25Jan 26Apr 26Jul 26MEDHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +2.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Feb 2026Stephens & Co.MaintainsEqual-Weight$15 → $12
19 Feb 2026Stephens & Co.MaintainsEqual-Weight—
19 Feb 2025DA DavidsonMaintainsNeutral—
5 Nov 2024DA DavidsonUpgradeNeutral—
22 July 2024DA DavidsonMaintainsUnderperform—
5 June 2024DA DavidsonDowngradeUnderperform—
30 Apr 2024DA DavidsonMaintainsNeutral—
21 Feb 2024DA DavidsonMaintainsNeutral—
13 Oct 2023Stephens & Co.InitiatesEqual-Weight—
8 Aug 2023DA DavidsonMaintainsNeutral—
31 July 2023DA DavidsonMaintainsNeutral—
2 May 2023DA DavidsonMaintainsNeutral—
22 Feb 2023DA DavidsonMaintainsNeutral—
4 Nov 2022DA DavidsonDowngradeNeutral—
4 Aug 2022DA DavidsonMaintainsBuy—
4 Aug 2022JefferiesDowngradeHold—
2 June 2022DA DavidsonMaintainsBuy—
24 Feb 2022DA DavidsonMaintainsBuy—
8 Nov 2021DA DavidsonMaintainsBuy—
5 May 2021DA DavidsonMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MED appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Medifast, Inc. returned −19.2% against +16.3% for the S&P 500, dividends included.

MED vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Oct 25Jan 26Apr 26Jul 26MEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Medifast, Inc. (MED) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
531.5×

Cheaper than 1% of US stocks

Price / sales
0.4×

Cheaper than 84% of US stocks

Price / book
0.6×

Cheaper than 82% of US stocks

EV / EBITDA
3.3×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
−27.6%

Higher than 9% of US stocks

Earnings growth (YoY)
−27.6%

Higher than 17% of US stocks

Gross margin
69.9%

Higher than 82% of US stocks

Operating margin
−5.7%

Higher than 27% of US stocks

Net margin
−8.1%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−12.4%

Higher than 34% of US stocks

Return on assets
−4.6%

Higher than 32% of US stocks

Dividend yield
54.9%

Higher than 97% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Medifast, Inc. (MED) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medifast, Inc. has a market value of $133.7M and an enterprise value of −$18.6M.

  • Revenue in the twelve months to 30 June 2026: $316.9M. The latest quarter shrank 27.6% year on year.

  • Net income over the same four quarters: −$25.6M, a −8.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.33.

  • Free cash flow in the twelve months to 30 June 2026: $4.0M.

  • Medifast, Inc. spent $813K on share buybacks and $170K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 11.2M.

  • Trailing P/E: 531.5×; forward P/E: −42.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 54.91%, paying out 0% of earnings.

  • Medifast, Inc. employs 380 people — $834K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

MED vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPersonal Services
CompanyMarket capTKN rank
MEDMedifast, Inc.$133.7M
48
RGSRegis Corp.$68.2M
79
CSVCarriage Services, Inc.$487.0M
30
CLIKClick Holdings Ltd.$10.4M
3
LANVLanvin Group Holdings Ltd.*$135.6M
21
TLYSTilly's, Inc.*$129.9M
98
COOKTraeger, Inc.*$136.8M
38

* Nearest Consumer Cyclical names by size — few personal services companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Medifast, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MED news & analysis

Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?

Zacks Investment Research · 4 Sept 2026positive

Medifast is advancing its "3.0" strategy, pivoting toward metabolic health with an eye toward broader growth, greater efficiency, and a return to profitability. The strategy is taking shape as the company works to restore profitable growth.

Why it matters — MED watchers would care because the 3.0 strategy signals the company's direction for restoring profitable growth and could determine whether it can turn around its business model.

Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?

Zacks Investment Research · 2 Sept 2026negative

Medifast (MED) reported earnings 30 days ago, and its stock has declined 7.6% since that report. The article examines what may be next for the stock following this post-earnings drop.

Why it matters — MED watchers would care because the 7.6% decline since the last earnings report reflects recent market reaction and signals that investors are closely tracking the company's post-earnings performance.

Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update

PRNewsWire · 2 Sept 2026neutral

Ocius Technology announced it will add sonar systems to its Bluebottle fleet, according to a NYSE pre-market daily advisory issued from the trading floor in New York.

Why it matters — A MED watcher would care because this NYSE-issued content update touches on market activity that could relate to companies within the same news cycle.

Medifast® Announces the Launch of the Medifast Metabolic Health Institute™

Business Wire · 27 Aug 2026positive

Medifast, Inc. announced the launch of the Medifast Metabolic Health Institute, which consolidates the company's clinical research, scientific expertise, and educational resources into a single body focused on advancing metabolic health through rigorous research and evidence-based education. The launch follows the July introduction of Trilivy, which replaced OPTAVIA as the company's product.

Why it matters — A Medifast watcher would care because the institute signals a strategic commitment to solidifying the company's position in the metabolic health space following the recent transition from OPTAVIA to its Trilivy product.

Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?

Zacks Investment Research · 26 Aug 2026positive

Medifast launched Trilivy, signaling a major shift toward metabolic health, backed by a 10-year roadmap and a growing focus on the GLP-1 market.

Why it matters — A MED watcher would care because this launch positions the company in the expanding metabolic-health and GLP-1 space that is central to its long-term strategy.

FAQ

Frequently asked questions about MED stock

What is the MED stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Medifast, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MED stock a buy right now?

Of the 1 analysts covering Medifast, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medifast, Inc. 48 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MED?

As at 17 Sept 2026, Medifast, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will MED stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Medifast, Inc. 48 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MED stock forecast for 2030?

No analyst covering Medifast, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has MED stock performed over the past year?

Medifast, Inc. returned -19.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medifast, Inc. do?

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health.

What is the latest news on MED?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?". Medifast is advancing its "3.0" strategy, pivoting toward metabolic health with an eye toward broader growth, greater efficiency, and a return to profitability. The strategy is taking shape as the company works to restore profitable growth.

Company

About Medifast, Inc.

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines. Medifast Inc. sells a range of products including shakes, bars, soups, cereals, and other nutrition items designed for convenience and consistency within its program model. Its business serves individuals seeking weight loss and long-term healthy living support, while also relying on a network of independent coaches and digital ordering channels to deliver its services. Headquartered in Baltimore, Maryland, Medifast Inc. plays a specialized role in the broader wellness market by integrating products, guidance, and behavior-change support into a single customer experience.

CEO Mr. Nicholas M. Johnson · 380 employees · United States · https://medifastinc.com